Stable formulations of anti-CTLA4 antibodies alone and in combination with anti-programmed death receptor 1 (PD-1) antibodies and their methods of use

MA50501AUndetermined Publication Date: 2020-09-09MERCK SHARP & DOHME CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MA50501
Authority / Receiving Office
MA · MA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-05-02
Filing Date
2018-05-01
Publication Date
2020-09-09
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.